Seelos Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Seelos Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Seelos Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:SEEL.Q - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	2	4	-13	-13	N/A
3/31/2024	2	-27	-18	-18	N/A
12/31/2023	2	-38	-24	-24	N/A
9/30/2023	2	-51	-35	-35	N/A
6/30/2023	1	-81	-40	-40	N/A
3/31/2023	1	-73	-55	-55	N/A
12/31/2022	N/A	-74	-62	-62	N/A
9/30/2022	N/A	-82	-67	-67	N/A
6/30/2022	N/A	-73	-66	-66	N/A
3/31/2022	N/A	-61	-55	-55	N/A
12/31/2021	N/A	-66	-49	-49	N/A
9/30/2021	N/A	-45	-34	-34	N/A
6/30/2021	N/A	-39	-28	-28	N/A
3/31/2021	N/A	-33	-26	-26	N/A
12/31/2020	N/A	-19	-21	-21	N/A
9/30/2020	N/A	-23	-23	-23	N/A
6/30/2020	0	-22	-21	-21	N/A
3/31/2020	0	-21	-18	-18	N/A
12/31/2019	0	-51	-19	-19	N/A
9/30/2019	0	-42	-15	-15	N/A
6/30/2019	N/A	-40	-12	-12	N/A
3/31/2019	N/A	-38	-9	-9	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-1	-1	N/A
6/30/2018	N/A	-2	-1	-1	N/A
3/31/2018	N/A	-2	N/A	-1	N/A
12/31/2017	N/A	-12	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SEEL.Q's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if SEEL.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SEEL.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SEEL.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SEEL.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SEEL.Q's Return on Equity is forecast to be high in 3 years time

Seelos Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$0.41 loss

Consensus EPS estimates upgraded to US$0.34 loss

Consensus revenue estimates decrease by 26%

Consensus revenue estimates increase by 80%, EPS downgraded

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Recent updates

Seelos Therapeutics, Inc. Filed for Bankruptcy

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Price target decreased to US$8.58

We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely

Seelos: Superior Data, But Early Stage

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity